(NASDAQ: PCVX) Vaxcyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Vaxcyte's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PCVX's revenue for 2026 to be $19,350,620,700, with the lowest PCVX revenue forecast at $19,350,620,700, and the highest PCVX revenue forecast at $19,350,620,700. On average, 1 Wall Street analysts forecast PCVX's revenue for 2027 to be $1,844,759,173, with the lowest PCVX revenue forecast at $1,844,759,173, and the highest PCVX revenue forecast at $1,844,759,173.
In 2028, PCVX is forecast to generate $14,854,826,491 in revenue, with the lowest revenue forecast at $1,844,759,173 and the highest revenue forecast at $27,864,893,808.